Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.43 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.43 |
| ▸ | F10 known ✓ | P00742 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.42 |
| ▸ | ACR | P10323 | 3/20 | 0.42 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107802 | 0.83 | PRSS1 (0.48) | ALDH1A1HTTSMN1; SMN2TDP1PRSS1 | |
| SCHEMBL8127463 | 0.82 | CYP2D6 (0.55) | CYP2D6MAPK1ALDH1A1LMNAMAPT | |
| Guanidine SCHEMBL811270 | 0.81 | CYP2D6 (0.61) | CYP2D6MAPK1ALDH1A1LMNAMAPT | |
| SCHEMBL27984301 | 0.79 | CYP2D6 (0.50) | CYP2D6MAPK1ALDH1A1LMNAMAPT | |
| Thiourea SCHEMBL1577311 | 0.78 | CYP2D6 (0.58) | CYP2D6MAPK1ALDH1A1LMNAMAPT | |
| SCHEMBL8112871 | 0.76 | ALDH1A1 (0.58) | CYP2D6MAPK1ALDH1A1LMNAMAPT | |
| Urea SCHEMBL11794762 | 0.75 | ALDH1A1 (0.57) | CYP2D6MAPK1ALDH1A1LMNAMAPT | |
| Hno SCHEMBL3391939 | 0.75 | GAA (0.56) | CYP2D6MAPK1ALDH1A1LMNAMAPT | |
| Hydrazine SCHEMBL8861759 | 0.75 | ALDH1A1 (0.58) | CYP2D6MAPK1ALDH1A1LMNAMAPT | |
| Hydroxyamine SCHEMBL599912 | 0.75 | ALDH1A1 (0.58) | CYP2D6MAPK1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11278549-B2 | Method of treating obesity | MCMASTER UNIVERSITY (CA) | 2022-03-22 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20090220429-A1 | METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | METIS CURA EHF (IS) | 2009-09-03 | — | — | US | claimed |
| CN-101155548-A | Methods and systems for assessing neurological conditions | MENTIS CURA EHF (IS) | 2008-04-02 | — | — | CN | claimed |
| EP-1861003-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | Mentis Cura ehf. (IS) | 2007-12-05 | — | — | EP | claimed |
| WO-2006094797-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | MENTIS CURA EHF. (IS) | 2006-09-14 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20010023254-A1 | Psychological disorders | CINCINNATI, UNIVERSITY OF | 2001-09-20 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278549-B2 | Method of treating obesity | GPR119, HTR2A, GIPR | FLT1 4142/4885FLT4 3736/4885KDR 3185/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | FLT1 922/4885FLT4 555/4885KDR 854/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | FLT1 3883/4885FLT4 4013/4885KDR 3186/4885 |
| US-20010023254-A1 | Psychological disorders | DRD2, DRD3, DRD1 | FLT1 4876/4885FLT4 4874/4885KDR 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.